Bristol Myers Squibb announced that the European Commission has granted approval for Breyanzi, a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. This approval covers all European Union member states.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- Bristol-Myers announces Reblozyl sBLA accepted for priority review
- Immix says Bristol-Myers exercises option, enters license for TCR-T candidate
- Bristol-Myers reports ‘positive’ results from TRANSCEND studies
- Bristol-Myers price target lowered to $65 from $66 at Barclays
- Bristol-Myers price target lowered to $72 from $78 at Credit Suisse